Of the 20 participants with major depressive disorder, 19 have begun their dosing regimen and eight individuals have successfully completed the full treatment.
MindBio Therapeutics provided an update Dec. 20 on its Phase 2a LSD trial for depression.
The Australian company is conducting the trial at the University of Auckland in New Zealand using its MB22001 titratable form of LSD for at-home microdosing.
Of the 20 participants with major depressive disorder, 19 have begun their dosing regimen and eight individuals have successfully completed the full treatment.
The company expects to have results from the trial in the first quarter of 2024, said Justin Hanka, chief executive officer of MindBio, in a recent video update.
At-home administration is essential for assessing the safety and efficacy of psychedelics within the community, MindBio says.
The company says the trial builds on positive outcomes from a Phase 1 LSD microdosing clinical trial completed in 2022.
The Phase 1 trial revealed no serious adverse events, the company said.
Simultaneously, MindBio is conducting a Phase 2B trial addressing existential distress in late-stage cancer patients. This randomized and double-blind trial involving 40 participants seeks to determine the effectiveness of MB22001. If successful, the substance could potentially be made accessible to end-of-life patients through special drug access schemes before obtaining regulatory approvals.
“As we progress through these clinical trials, we inch closer to our commercialization objective that would see MB22001 used broadly, safely, with lower side effects and more effectively for treating depression in the community,” Hanka said.